KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Astellas Pharma Inc
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Alterome Therapeutics, Inc.
Erasca, Inc.
Vanderbilt-Ingram Cancer Center
Tizona Therapeutics, Inc
GlaxoSmithKline
Bristol-Myers Squibb
Synthorx, Inc, a Sanofi company
M.D. Anderson Cancer Center
Mirati Therapeutics Inc.
BioAtla, Inc.
Pfizer
Sanofi
Blokhin's Russian Cancer Research Center
University of California, San Diego
Celgene
GlaxoSmithKline
Al-Azhar University
Biond Biologics
Fox Chase Cancer Center
Eisai Inc.
Nektar Therapeutics
NKGen Biotech, Inc.
Eli Lilly and Company
M.D. Anderson Cancer Center
Sichuan Cancer Hospital and Research Institute
University of Chicago
Bayer
Eli Lilly and Company
Novartis
Merck Sharp & Dohme LLC
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
AbbVie
Hoffmann-La Roche
GERCOR - Multidisciplinary Oncology Cooperative Group
University of Pittsburgh
University of Kansas Medical Center
Merck KGaA, Darmstadt, Germany
University of Pittsburgh
Fox Chase Cancer Center
University Hospital, Ghent
Hoffmann-La Roche
Hoffmann-La Roche
Eli Lilly and Company
Eli Lilly and Company